Please assess the completion status of the following clinical trial:

Trial Title: Genomic Landscape of Ceritinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma.~* Presence of known ALK gene rearrangement.~* Consented to HRPO# 201305031 (Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma) with an existing specimen prior to initiation of treatment with ceritinib.~* At least 18 years of age.~* Received treatment with standard of care ceritinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).